This Article Full Text Full Text (PDF) All Versions of this Article: 200603-406OCv1 174/11/1199    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shigemura, N. Articles by Sawa, Y. Search for Related Content PubMed PubMed Citation Articles by Shigemura, N. Articles by Sawa, Y.

Lung Tissue Engineering Technique with Adipose Stromal Cells Improves Surgical Outcome for Pulmonary Emphysema

Division of Cardiothoracic Surgery, Department of Surgery, Division of Molecular Regenerative Medicine, Course of Advanced Medicine, and Medical Center for Translational Research, Osaka University Graduate School of Medicine, Osaka, Japan

Correspondence and requests for reprints should be addressed to Yoshiki Sawa, M.D., Department of Surgery, Osaka University Graduate School of Medicine, E1, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. E-mail: sawa{at}surg1.med.osaka-u.ac.jp

Rationale and Objectives: Hepatocyte growth factor (HGF) is a potent regenerative factor generated after a lung injury, and HGF supplementation after surgical reduction has been shown to enhance compensatory growth in remnant lungs and improve pathophysiologic conditions in a rat model of emphysema. Adipose tissue–derived stromal cells (ASCs) produce a large amount of angiogenic factors, including HGF. After lung volume reduction surgery (LVRS), we treated rats by implanting HGF-secreting ASCs with a scaffold onto the remnant lung tissue to determine the usefulness of this technique for treating respiratory dysfunction.

Methods and Main Results: Cells were isolated from rat inguinal adipose tissue and characterized by flow cytometry. ASCs were cultured on a polyglycolic acid felt sheet as a sealant material, and were shown to secrete significantly greater amounts of HGF than other angiogenic factors. Next, ASCs on polyglycolic acid felt sheets were used to cover the cut edge of the remaining lungs after LVRS for emphysema in rats. One week after implantation of the ASCs, both alveolar and vascular regeneration were significantly accelerated as compared with the rats that underwent LVRS alone. Consequently, gas exchange and exercise tolerance were also significantly restored, with these good results persisting for more than 1 mo.

Conclusions: The present findings demonstrate the therapeutic potential of cell therapy using ASCs with a scaffold for selective delivery of HGF to remnant lungs, which resulted in enhancement of compensatory growth, after surgical resection. This approach may provide a new strategy for lung tissue engineering to improve LVRS outcome.

Key Words: adipose tissue • angiogenesis • hepatocyte growth factor • lung • pulmonary emphysema • tissue engineering

AT A GLANCE COMMENTARY Scientific Knowledge on the Subject Surgical outcome for pulmonary emphysema (lung volume reduction surgery) is not satisfactory, although a small portion of patients can enjoy its current benefits. What This Study Adds to the Field Tissue engineering techniques with cell-based therapy in the lung would contribute to overcoming the present limitations in the surgical outcome for pulmonary emphysema.

 

This article has been cited by other articles:

				D. J. Weiss, J. K. Kolls, L. A. Ortiz, A. Panoskaltsis-Mortari, and D. J. Prockop Stem Cells and Cell Therapies in Lung Biology and Lung Diseases Proceedings of the ATS, July 15, 2008; 5(5): 637 - 667. [Full Text] [PDF]

				K. F. Rabe, B. Beghe, F. Luppi, and L. M. Fabbri Update in Chronic Obstructive Pulmonary Disease 2006 Am. J. Respir. Crit. Care Med., June 15, 2007; 175(12): 1222 - 1232. [Full Text] [PDF]